Cognitive training to help brain function in people getting CAR-T therapy for relapsed or refractory blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-arm study enrolls 90 adults with relapsed or refractory B-cell hematologic cancers who are receiving FDA-approved CAR-T therapy. The online I-CAN cognitive training program is delivered around CAR-T treatment to try to bolster cognitive function and neuroplasticity. Researchers will measure cognitive function, neurotoxicity, distress, frailty, and aging-related biomarkers before and after the program, with follow-up across multiple timepoints. Additional analyses will explore how molecular aging markers relate to cognition, frailty, and treatment factors, and how the program may impact healthcare utilization. The trial includes biospecimen collection, cognitive intervention, electronic health record review, and survey administration.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients \>= 18 years of age
* Diagnosed with relapsed/refractory multiple myeloma (MM) or B-cell non-Hodgkin lymphoma (B-NHL)
* Expected to receive an Food and Drug administration (FDA)-approved CAR-T cellular treatment
* English literacy

Exclusion Criteria:

* Patients expected to live \< 6 months
* Patients with major medical disorder known to affect cognition, such as stroke, encephalitis, traumatic brain injury, brain surgery
* Confirmed Alzheimer disease or other dementia
* Previous central nervous system (CNS) radiation
* Active intrathecal therapy at time of enrollment

Where it's running

• Ohio State University Comprehensive Cancer Center
  Columbus, Ohio, United States Recruiting

Study contacts

• Principal investigator: Ashley E Rosko, MD — Ohio State University Comprehensive Cancer Center
• Study coordinator: The Ohio State University Comprehensive Cancer Center
• Email: OSUCCCClinicaltrials@osumc.edu
• Phone: 800-293-5066

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma

  This phase 2 trial tests whether infliximab can prevent cytokine release syndrome in patients with relapsed or refractory multiple myeloma who are being treated with teclistamab or talquetamab.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07657312

• Pomalidomide after CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma

  This phase 1 study tests whether pomalidomide, given after CD19 CAR T-cell therapy, is safe and may help people whose CD19+ B-cell leukemia or lymphoma has come back or not responded.

  Recruiting Phase 1 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07532525

• Teclistamab plus pomalidomide vs standard therapy for relapsed multiple myeloma

  This study tests whether the combination of teclistamab and pomalidomide can work better than the usual regimen (carfilzomib, pomalidomide, and dexamethasone) for adults whose multiple myeloma has returned after some improvement.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Duarte, California · NCT07463807

• NK cell therapy with epcoritamab and tafasitamab for relapsed or treatment‑resistant B‑cell lymphoma

  This trial will try whether adding donor-derived ONC-PluReceptor NK cells to the antibodies epcoritamab and tafasitamab helps control relapsed or refractory CD19/CD20-positive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07283679

• Response-based lowering of linvoseltamab doses for relapsed or refractory multiple myeloma

  This trial tests whether lowering linvoseltamab doses for people with relapsed or refractory multiple myeloma can control the cancer while reducing side effects.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07181941

• Daratumumab‑hyaluronidase plus teclistamab vs standard daratumumab combinations for high‑risk relapsed or refractory multiple myeloma

  This phase 2 trial tests whether combining daratumumab with teclistamab helps people with high‑risk myeloma that has not responded to treatment or has come back, compared to usual daratumumab‑based therapies.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Coeur d'Alene, Idaho and 31 other locations · NCT06948084

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.